R
RenovoRx, Inc.
RNXTCIK 0001574094NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
$1.12M
Net Income
$-11.17M
Total Assets
—
Equity
—
Shares Out
45.10M
Op. Cash Flow
$-10.97M
Business
RenovoRx, Inc. is a life sciences company that offers RenovoCath, an FDA-cleared local drug‑delivery device, and is developing an intra‑arterial gemcitabine drug‑device combination (IAG) using its TAMP therapy platform for difficult‑to‑treat cancers. Its main products and services include the RenovoCath catheter, the Trans‑Arterial Micro‑Perfusion (TAMP) delivery platform, clinical development of IAG in a pivotal Phase III trial, and related physician training and commercial support. The company operates two principal business activities: clinical‑stage drug‑device development (IAG/TIGeR‑PaC) and commercial‑stage device sales of RenovoCath. It targets the U.S. market, distributing RenovoCath directly to hospitals and cancer treatment centers through a contract manufacturing relationship and discussions with potential distribution partners and clinical sites.
Summary from filing dated 2025-04-01
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 1 | 43,000 | — | — | — | |
| Cost of Revenue | 327,000 | 0 | — | — | — | |
| Gross profit | 796,000 | 43,000 | — | — | — | |
| Research and development | 6 | 6 | 6 | 4 | 3 | |
| Selling, general and administrative | 7 | 5 | 6 | — | — | |
| Total operating expenses | 13 | 11 | 11 | 10 | 6 | |
| Loss from operations | −13 | −11 | −11 | −10 | −6 | |
| Change in fair value of warrant liability | 915,000 | 2 | 2 | — | — | |
| Interest income, net | 427,000 | 384,000 | 108,000 | 57,000 | −834,000 | |
| Total other income, net | 1 | 2 | 1 | 61,000 | −653,000 | |
| Net loss | −11 | −9 | −10 | −10 | −6 | |
| Net loss per share - basic | −0.32 | −0.4 | −0.99 | −1.09 | −1.21 | |
| Net loss per share - diluted | −0.32 | −0.4 | −0.99 | −1.09 | — | |
| Weighted average shares of common stock - basic | 35 | 22 | 10 | 9 | 5 | |
| Weighted average shares of common stock - diluted | 35 | 22 | 10 | 9 | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 7 | 7 | 1 | 4 | 15 | |
| Accounts receivable | 139,000 | 43,000 | — | — | — | |
| Prepaid expenses | 324,000 | 328,000 | 168,000 | — | — | |
| Inventory | 189,000 | 0 | — | — | — | |
| Other current assets | 217,000 | 303,000 | 24,000 | — | — | |
| Total current assets | 8 | 8 | 1 | 7 | 16 | |
| Operating lease right-of-use asset | 190,000 | 278,000 | — | — | — | |
| Property and equipment, net | 12,000 | 12,000 | — | — | — | |
| Total assets | 8 | 8 | 1 | 7 | 16 | |
| Accounts payable | 799,000 | 586,000 | 561,000 | 534,000 | 525,000 | |
| Accrued expenses and other current liabilities | 1 | 1 | 614,000 | 568,000 | 413,000 | |
| Total current liabilities | 2 | 2 | 1 | 1 | 938,000 | |
| Common stock warrant liability | 604,000 | 2 | 3 | — | — | |
| Operating lease liability, net of current portion | 107,000 | 212,000 | — | — | — | |
| Total liabilities | 3 | 4 | 4 | 1 | 938,000 | |
| Commitments and contingencies | — | — | — | — | — | |
| Convertible preferred stock, $0.0001 par value; 15,000,000 shares authorized as of December 31, 2025 and 2024, respectively; zero shares issued and outstanding at December 31, 2025 and 2024, respectively | 0 | 0 | — | — | — | |
| Common stock, $0.0001 par value; 250,000,000 shares authorized at December 31, 2025 and 2024, respectively; 36,613,916 and 24,034,672 shares issued and outstanding at December 31, 2025 and 2024, respectively | 4,000 | 2,000 | 1,000 | 1,000 | 1,000 | |
| Additional paid-in capital | 67 | 55 | 38 | 37 | 37 | |
| Accumulated deficit | −61 | −50 | −41 | −31 | −21 | |
| Total Stockholders equity | 5 | 4 | 3 | 6 | 15 | |
| Total liabilities and stockholders equity | 8 | 8 | 1 | 7 | 16 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation expense | 1 | 1 | 1 | 644,000 | 147,000 | |
| Non-cash lease expense | 88,000 | 7,000 | — | — | — | |
| Fair value adjustment on common warrants | −915,000 | −2 | −2 | — | — | |
| Depreciation | 2,000 | 0 | — | — | — | |
| Accounts receivable | −96,000 | 0 | — | — | — | |
| Inventory | −189,000 | 0 | — | — | — | |
| Prepaid expenses | 90,000 | −160,000 | — | — | — | |
| Other current assets | 0 | −221,000 | — | — | — | |
| Accounts payable | 213,000 | 25,000 | 27,000 | — | 363,000 | |
| Accrued expenses | −265,000 | 636,000 | 46,000 | 155,000 | 342,000 | |
| Net cash used in operating activities | −11 | −9 | −10 | −9 | −6 | |
| Purchase of property and equipment | −2,000 | −12,000 | — | — | — | |
| Net cash used in investing activities | −2,000 | −12,000 | 2 | −2 | −15,000 | |
| Proceeds from common stock and pre-funded common stock warrants | 12 | 17 | 5 | — | 15 | |
| Costs of issuance of common stock upon private placement | −1 | −2 | — | — | — | |
| Proceeds from exercise of common stock warrants | 25,000 | 33,000 | — | — | 3 | |
| Proceeds from exercise of stock options | 17,000 | 69,000 | 8,000 | 42,000 | 107,000 | |
| Net cash provided by financing activities | 11 | 15 | 5 | 42,000 | 19 | |
| Change in cash and cash equivalents | −130,000 | 6 | −3 | −11 | 13 | |
| Cash paid for income taxes | 1,000 | 2,000 | 38,000 | — | — | |
| Cash paid for interest | 16,000 | 21,000 | 14,000 | — | — | |
| Right-of-use assets obtained in exchange for lease obligations | 0 | 285,000 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro